Home Your basket
• Focus on the BPPV: Semont...
   Price 12.50 €
• Distortion product otoaco...
   Price 10.50 €
• Laryngeal neuroendocrin c...
   Price 5.50 €
• Exophthalmos arising from...
   Price 10.50 €
• Management of cervical ce...
   Price 10.50 €
• Facial nerve outcome af...
   Price 12.50 €
• Otosclerosis among patien...
   Price 10.50 €
• Metastatic angiosarcoma t...
   Price 5.50 €
• Rejuvenation of the eye: ...
   Price 10.50 €
• Hyperglycemia after intra...
   Price 8.50 €
• Total ossicular reconstru...
   Price 10.50 €
• Management of swallowing ...
   Price 8.50 €
• Sphenochoanal polyp: Repo...
   Price 5.50 €
• Endoscopic sphenoid proce...
   Price 8.50 €
• Diagnosis of submandibula...
   Price 10.50 €
• The Voice Handicap Index:...
   Price 10.50 €
• Treatment of severe epist...
   Price 5.50 €
• Saddle nose surgery: Long...
   Price 10.50 €
• Massive bone dystrophic l...
   Price 5.50 €
• Validation of a self-asse...
   Price 10.50 €
• Transsexuality: Speech th...
   Price 10.50 €
• Botulinum toxin and rejuv...
   Price 10.50 €
• Deafness in adults. Study...
   Price 10.50 €
• Treatment and rehabilitat...
   Price 10.50 €
• Defects in accuracy of th...
   Price 10.50 €
• Eye rings: Morphological ...
   Price 10.50 €
• Ethmoid-nasal meningioma ...
   Price 10.00 €
• Assessment of migraine re...
   Price 8.50 €
• Laryngeal papillomatosis ...
   Price 5.50 €
• A report of two cases of ...
   Price 5.50 €
• Diagnosis of non organic ...
   Price 8.50 €
• Benign paroxysmal positio...
   Price 5.50 €
• Art and nose....
   Price 8.50 €
• Nasal cutaneous cryptococ...
   Price 5.50 €
• Communication disorders m...
   Price 5.50 €
• Frontal sinus osteoma com...
   Price 5.50 €
• Total pharyngolayngectomy...
   Price 10.50 €
• International Conference ...
   Price 5.50 €
• Oto-rhino-laryngology and...
   Price 10.50 €
• Occult otologic fistulas ...
   Price 5.50 €
• Salivary gland choristoma...
   Price 5.50 €
• "Sonorous man" - an appro...
   Price 8.50 €
• Middle ear osteoma: A rar...
   Price 8.50 €
• Surgical management of ma...
   Price 10.50 €
• Endoscopic resection of s...
   Price 10.50 €
• Cervical lymph node metas...
   Price 8.50 €
• Impaired laryngeal mobili...
   Price 10.50 €
• Pathophysiology, assessme...
   Price 12.50 €
• Treatment failures in ben...
   Price 10.50 €
• Human skull development a...
   Price 10.50 €
• Recovery of saccular func...
   Price 8.50 €
• Effect of vestibular neur...
   Price 10.50 €
• Functional anatomy of the...
   Price 14.00 €
• Prospective evaluation of...
   Price 10.50 €
• Reliability of CT-Scan in...
   Price 8.50 €
• Thyroid tuberculosis asso...
   Price 5.50 €
• Implementation of the Eur...
   Price 10.50 €
• Botulinum toxin, descript...
   Price 12.50 €
• Vocal effectiveness in sp...
   Price 10.50 €
• Temporary loss of visual ...
   Price 8.50 €
• The eye movement autophon...
   Price 14.00 €
• Cervicofacial cellulitise...
   Price 10.50 €
• Aesthetic profiloplasty: ...
   Price 10.50 €
• Guidelines for the clinic...
   Price 12.00 €
• Evaluation and treatment ...
   Price 8.50 €
• Anosmia following superio...
   Price 5.50 €
• Assessing efficacy of voi...
   Price 5.50 €
• The “Deglutition Handicap...
   Price 10.50 €
• Post operative Caldwell-L...
   Price 10.00 €
• High click stimulus repet...
   Price 10.50 €
• Voice related quality of ...
   Price 10.50 €
• Does indermil glue improv...
   Price 5.50 €
• Notes on voice and speech...
   Price 8.50 €
• Validation of a self asse...
   Price 10.50 €
• Presentation of a prototy...
   Price 10.50 €
• Clinical Practice Guideli...
   Price 12.00 €
• Nasal polyposis and olfac...
   Price 10.50 €
• Autologous bone pate in m...
   Price 10.50 €
• Moderate leukocyte infilt...
   Price 10.50 €
• Otomycosis: Clinical and ...
   Price 5.50 €
• XVIth World Congress of O...
   Price 8.50 €
• Cleft palate and otitis m...
   Price 10.50 €
• Evaluation of the efficie...
   Price 10.50 €

Total Order 763.50 €

contents
2019
   N# 1 |
2018
   N# 1 | 2 | 3 | 4 | 5 |
2017
   N# 1 | 2 | 3 | 4 | 5 |
2016
   N# 1 | 2 | 3 | 4 | 5 |
2015
   N# 1 | 2 | 3 | 4 | 5 |
2014
   N# 1 | 2 | 3 | 4 | 5 |
2013
   N# 1 | 2 | 3 | 4 | 5 |
2012
   N# 1 | 2 | 3 | 4 | 5 |
2011
   N# 1 | 2 | 3 | 4 | 5 |
2010
   N# 1 | 2 | 3 | 4 | 5 |
2009
   N# 1 | 2 | 3 | 4 | 5 |
2008
   N# 1 | 2 | 3 | 4 | 5 |
2007
   N# 1 | 2 | 3 | 4 | 5 |
2006
   N# 1 | 2 | 3 | 4 | 5 |
2005
   N# | 1 | 2 | 3 | 4 | 5 |
2004
   N# 1 | 2 | 3 | 4 | 5 |
2003
   N# 1 | 2 | 3 | 4 | 5 |
2002
   N# 1 | 2 | 3 | 4 | 5 |
2001
   N# 1 | 2 | 3 | 4 | 5 |
2000
   N# | 1 | 2 | 3 | 4 | 5 |
1999
   N# 1 | 2 | 3 | 4 | 5 |
1998
   N# 1 | 2 | 3 | 5 |
1997
   N# 1 | 2 | 3 | 4 | 5 |
1996
   N# 4 | 5 |

Click on the number of the review to see the content
Teaching bulletin CME
List of all teaching bulletins CME.
Editor reading committee
Editor reading committee.
To publish...
Instructions for authors
Archives Press and Books
Select of books and press articles.
Mailing list
News information letter.
Subscription prices


If you wish to adjust the size of the displayed characters, click in the high menu on "Your account" and choose the desired size.



  Contents > Previous page > Article detail print Order
o Issue N# 4 - 2008 o

OTONEUROLOGY

Disability in patients with Menière’s disease following the use of two different treatment modalities: Betahistine and intratympanic gentamicin


Authors : Enrique-Gonzalez A, Sánchez-Ferrándiz N, Pérez-Fernández N. (Pamplona)

Ref. : Rev Laryngol Otol Rhinol. 2008;129,4:249-254.

Article published in english
Downloadable PDF document english



Summary : Objective: The objective of this study was to assess the level of residual disability and handicap in patients with Menière’s disease (MD) that were free of new vertigo spells 2 years after having been administered treatment with either oral medication or with intratympanic gentamcin. Setting: University hospital. Tertiary medical center. Material and method: 40 patients with MD were included in this study, of which 20 were treated with oral medication (betahistine) and 20 with intratympanic gentamicin; intratympanic gentamicin was for patients considered failures for the oral medication treatment. All of them are free of new vertigo in the 16-24 month period after beginning the treatment. They were matched by age and disease duration. Disability and handicap were assessed with conventional questionnaires at the time of inclusion and 2 years after beginning oral medication or ended the intratympanic gentamicin treatment. According to the treatment two groups were created: oral medication treatment and intratympanic gentamicin treatment. Results: The amount of disability before treatment was higher in patients treated with intratympanic gentamicin than in those under oral medication; However, after treatment when no more vertigo spells takes place, this disability is significantly reduced and becomes similar for both groups of patients. In patients treated with oral medication the items reflecting the intensity of vertigo spell, the impact of vertigo in daily activities, the perception of quality of life and level of somatization do not show a significant reduction. Conclusion: The number or frequency of vertigo spells are very relevant for the process of disability and handicap of patients with MD when that is low or when oral medication is sufficient to eliminate vertigo spells. However when that number is high and the only possibility to arrest those vertigo spells is the use of intratympanic gentamicin, fear of vertigo must be considered as an associated problem for the patient.

Price : 10.50 €      order
|


Subscribe online - Pay by credit card!


© Copyright 1999-2024 - Revue de Laryngologie   Réalisation - Hébergement ELIDEE